Impel NeuroPharma Stock

impelnp.comHealthcareFounded: 2008Funding to Date: $122.85MM

Impel NeuroPharma is a biotechnology company devoted to creating life-changing, innovative therapies for central nervous system (CNS) diseases.

Register for Details

For more details on financing and valuation for Impel NeuroPharma, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

Enterprise Value (based on primary financings)

Powered by Forge Data
Enterprise Value

View Enterprise Value for Impel NeuroPharma.

Register Today

Team

Management Team

Jon Congleton
Chief Executive Officer, President & Board Member
Meghan Swardstrom
Vice President, Clinical Operations
Ellen Lubman
Chief Business Officer
Scott Youmans
Senior Vice President, Engineering
Mike Malafronte
Vice President of Quality Assurance
John Hoekman Ph.D
Co-Founder, Chief Scientific Officer & Board Member
Lynn Gold Ph.D
Senior Vice President, Regulatory
Stephen Shrewsbury
Chief Medical Officer

Board Members

Ali Satvat
Kohlberg Kravis Roberts
H. Stewart Parker
Mahendra Shah Ph.D
Vivo Capital
David Allison Ph.D
5AM Ventures
Diane Wilfong
John Hoekman Ph.D
Robert Mittendorff MD
Norwest Venture Partners
Aaron Royston MD
venBio
James Young Ph.D
5AM Ventures
Jon Congleton
Timothy Nelson

Other companies like Impel NeuroPharma in the Healthcare sector

Sector
Last Round Est. Valuation
$2.15B
Sector
Last Round Est. Valuation
$3.67B
Sector
Last Round Est. Valuation
$298.33MM
Sector
Last Round Est. Valuation
$4.26B
Sector
Last Round Est. Valuation
$1.08B
Sector
Last Round Est. Valuation
$334.19MM
Sector
Last Round Est. Valuation
$327.39MM
Sector
 
 
Sector
Last Round Est. Valuation
$500MM

News

Impel NeuroPharma, a biotech company focused on developing therapies for the treatment of CNS disorders, completed a $67.5m Series D financing